Tumor markers like carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) are routinely utilized in the management of colorectal cancer for diagnosis, prognosis, and surveillance, but their use is limited in medullary carcinoma. This evidence concerns the gene CEACAM5 and medullary thyroid gland carcinoma.